Main results
We included seven studies that included a total of 477 participants, most of whom had oxalate stones. Of these, three studies (247 participants) compared potassium citrate with placebo or no intervention; three (166 participants) compared potassium-sodium citrate with no intervention; and one (64 participants) compared potassium-magnesium citrate with placebo. Overall, quality of the reporting of the included studies was considered moderate to poor, and there was a high risk of attrition bias in two studies.
Compared with placebo or no intervention, citrate therapy significantly reduced the stone size (4 studies, 160 participants: RR 2.35, 95% CI 1.36 to 4.05). New stone formation was significantly lower with citrate therapy compared to control (7 studies, 324 participants: RR 0.26, 95% CI 0.10 to 0.68). The beneficial effect on stone size stability was also evident (4 studies, 160 participants: RR 1.97, 95% CI 1.19 to 3.26). Adverse events were reported in four studies, with the main side effects being upper gastrointestinal disturbance and one patient reported a rash. There were more gastrointestinal adverse events in the citrate group; however this was not significant (4 studies, 271 participants: RR 2.55, 95% CI 0.71 to 9.16). There were significantly more dropouts due to adverse events with citrate therapy compared to control (4 studies, 271 participants: RR 4.45, 95% CI 1.28 to 15.50). The need for retreatment was significantly less with citrate therapy compared to control (2 studies, 157 participants: RR 0.22, 95% CI 0.06 to 0.89).
Authors' conclusions
Citrate salts prevent new stone formation and reduce further stone growth in patients with residual stones that predominantly contain oxalate. The quality of reported literature remains moderate to poor; hence a well-designed statistically powered multi-centre RCT is needed in order to answer relevant questions concerning the efficacy of citrate salts.
P L A I N L A N G U A G E S U M M A R Y

Citrate salts for preventing and treating calcium containing kidney stones in adults
Kidney stones are one of the most common disorders of the urinary tract. They typically affect people aged 40 to 60 years of age and are twice as common in men than women although recent data suggest the risks are more equal. Calcium stones are the most common type of kidney stone and occur in two major forms: calcium oxalate and calcium phosphate. Kidney stones can cause severe abdominal pain and may require urgent treatment; they are one of the main causes of unscheduled admissions in urological practice.
Following treatment even first time stone formers have a risk for recurrence which increased with each subsequent stone. This increased risk of recurrence of stones is mainly attributed to altered composition of urine i.e. low citrate levels. Various prevention strategies including increased fluid intake and oral citrate supplements have been tried to modify the chemical composition of the urine. Citrate therapy is believed to stop crystals from growing into stones. The uncertainty of the true benefit of citrate therapy prompted this review.
We included seven studies (477 participants) in this review. Citrate salts significantly reduce stone size, prevent new stone formation, and results in stone size stability. People experienced more side effects, such as gastrointestinal disturbance, when using citrate salts than when using placebo, however the need for retreatment for stone removal was significantly less with citrate therapy.
B A C K G R O U N D Description of the condition
Kidney stones (renal stone disease) remain a public health problem around the world irrespective of geographical, cultural or racial backgrounds, with an incidence of approximately 0.1% to 0.3%. The lifetime risk is estimated to be between 10% and 20% in the Western world, but can be as high as 20% to 25% in the Middle East. Stone disease typically affects men two times more commonly than women and peak incidence is in the fourth to sixth decades of life (Magaret 2007; Pak 1998; Sarada 1991). Recent studies reported that the male:female ratio of patients with stones altered from 1.6:1 to 1.2:1 (Nowfar 2011),1.7:1 to 1.3:1 (Scales 2007). Between the mid-1970s and the mid-1990s, the prevalence of stone disease increased from 3.2% to 8.8% in the USA (Scales 2012; Stamatelou 2003). The stone recurrence rate without treatment is approximately 10% at one year, 33% at five years, 50% at 10 years, and 75% at 20 years (Sutherland 1985; Trinchieri 1999; Uribarri 1989) . Following first recurrence, the subsequent relapse risk is increased with a shortened time interval between recurrences (Strauss 1982). Most stones (60% to 80%) are composed of calcium salts (calcium oxalate, calcium phosphate, or both). The remainder are non-calcium stones such as struvite (5% to 15%), uric acid (5% to 10%), cystine (1%), or other substances (1%) (Miller 2007) . Kidney stone formation is based on supersaturation of urinary salts and crystal retention in the urinary tract. Urinary Inhibitors (citrate, pyrophosphate, magnesium, nephrocalcin) and promoters (cell debris, protein aggregates) are involved in the process and deficiency of inhibitors or abundance of promoters in the urine thought to predispose to stone disease (Magaret 2007) . The association of lower urinary citrate with kidney stones was first reported in 1941 (Kissin 1941) . Hypocitraturia has been reported in 15% to 63% of patients with kidney stones, presenting either as a single abnormality (10%) or in conjunction with other metabolic disorders (50%) (Zuckerman 2009). Urinary citrate inhibits the crystallisation of calcium salt, levels of less than 1.67 mmol/day (320 mg/day) is defined as hypocitraturia. Severe hypocitraturia is citrate excretion of less than 100 mg/day (0.53 mmol/day) and mild to moderate hypocitraturia is citrate excretion of 100 to 320 mg/day (0.53 to 1.67 mmol/day). These stones are typically composed of calcium phosphate and calcium oxalate. Most people with hypocitraturia are treated with potassium citrate to raise urine citrate levels to reduce the risk of recurrent stone formation. Minimally invasive techniques including extracorporeal shock wave lithotripsy (ESWL), percutaneous nephrolithotomy (PCNL) and flexible ureteroscopy have transformed the management of stone disease in the last three decades. These newer modalities involve a short hospital stay and, as ESWL can be performed without general anaesthesia, stone treatment, rather than prevention, has become an attractive option for clinicians. However, these interventions cost more to the health care organisations compared to preventive strategies. Preventive measures, which are cost effective, are needed because of the high rate of recurrence (Parks 1996) . Metabolic abnormalities are responsible for stone recurrence in 89% to 96% of patients (Levy 1995; Weisinger 1995) . A recent study observed a single urine metabolic risk factor in 67% and multiple factors in 27% of patients (Spivacow 2010). Active preventive treatment may be helpful in this group therefore it is desirable to offer specific recurrence preventive measures.
Description of the intervention
Hypocitraturia is recognised as a cause of kidney stone formation. Evidence from non-randomised studies and the European Association of Urology has recommended treatment of hypocitraturia (Turk 2014 
How the intervention might work
Citrate inhibits the formation of calcium oxalate stones by forming complexes with urinary calcium thereby reducing urinary calcium oxalate saturation. Citrate also inhibits the nucleation, growth, and agglomeration of calcium oxalate crystals (Kok 1986; Meyer 1975 ).
Why it is important to do this review
Various studies have demonstrated that citrate excretion is significantly lower in stone formers than in normal controls and citrate supplementation increases the urinary citrate level. A number of non-randomised studies have demonstrated a beneficial effect of citrate salts therapy in patients with kidney stones. Preminger 1988 demonstrated superiority of potassium citrate's over sodiumpotassium citrate. The European Association of Urology Guidelines on Urolithiasis (Turk 2014) recommends the use of citrate in hypocitraturia. However, the evidence base for this recommendation is limited. There is no consensus on the best formulation to treat recurrent kidney stone disease. This uncertainty warranted a systematic review to synthesise all available evidence on the efficacy, safety and acceptability of products containing citrate salts to assist people with stone disease and to reduce recurrence by creating good evidence-based treatment decisions.
O B J E C T I V E S
The objective of this review was to determine the efficacy and adverse events associated with citrate salts for the treatment and prevention of calcium containing kidney stones.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included randomised controlled trials (RCTs) that assessed the efficacy and adverse events associated with citrate salts for the treatment and prevention of kidney stones.
Types of participants
Inclusion criteria
• Age: patients aged 16 years or older • Stone characteristics:
• Primary or residual kidney stones post ESWL/post ureteroscopic lithotripsy/PCNL, or
• Active stone formers rendered stone-free following intervention who received citrate therapy for ≥ 6 months.
Exclusion criteria
• Patients with allergies or who are contraindicated to receive citrate salts
• Pregnant women and children with kidney stones • Kidney impairment (estimated glomerular filtration rate (eGFR) < 30 mL/min/1.73m²).
Types of interventions
• Oral citrate therapy administered to treat or prevent kidney stones and compared to placebo or no intervention.
• We assessed only those interventions that had a minimum treatment duration of at least six months.
• Studies comparing citrate salts with other pharmacological interventions for preventing kidney stones were excluded.
Types of outcome measures Primary outcomes
• Reduction in stone size (reduced residual fragments or complete disappearance) or reduction in stone recurrence rate (new stone formation) documented on plain abdominal radiography or intravenous urography or computerised tomography (CT) at 6, 12 and 24 months after commencement of treatment.
• Stability of stone disease documented on plain abdominal radiography or intravenous urography or CT at 6, 12 and 24 months after commencement of treatment.
Secondary outcomes
• Retreatment rates (retreatment for residual stones) documented during follow-up
• Correction of urinary levels of stone promoters and inhibitors (i.e. alterations in the blood and urine metabolic parameters following treatment)
• Non-compliance with citrate salts • Serious adverse events and adverse events associated with the intervention (e.g. citrate-related side effects documented during and after therapy).
Search methods for identification of studies
Electronic searches
We searched the Cochrane Kidney and Transplant Specialised Register (to 29 July 2015) through contact with the Trials Search Coordinator using search terms relevant to this review. The Cochrane Kidney and Transplant Specialised Register contains studies identified from the following sources.
1. 
Data collection and analysis
Selection of studies
A list of titles and abstracts of potentially relevant clinical studies were generated by the search strategy and imported in to bibliographic software (EndNote®). This list was screened by two authors independently and fully published papers were retrieved where appropriate. These papers were further assessed to ensure they met the inclusion criteria of this review and data extraction. Disagreements were resolved by consultation with a third author. We did not impose any language or any other restrictions on any of these searches. Non-English papers were translated where required.
Data extraction and management
Data extraction was carried out independently by the two authors using standard data extraction forms. Studies reported in non-English language journals were translated before assessment. Where more than one publication of one study was noted, only the publication with the most complete data was included. Disagreements were resolved by consensus or referred to a third author. Quality of reporting of the studies was completed independently by one author using the CONSORT 2010 checklist (Schulz 2010). We contacted two authors (Lojanapiwat 2011; Soygur 2002) by email for further data, but unfortunately no responses were received.
Assessment of risk of bias in included studies
Risk of bias was independently assessed by two authors using the risk of bias assessment tool (Higgins 2011) (see Appendix 2) . Data were also assessed according to the method of randomisation, allocation concealment, adequate descriptions of numbers, and reasons for patient withdrawal, as detailed in the Cochrane Handbook for Systematic Review of Interventions (Higgins 2011).
Measures of treatment effect
For dichotomous outcomes (success, effectiveness, re-treatment, and serious adverse effects) results are expressed as risk ratios (RR) with 95% confidence intervals (CI). Where continuous scales of measurement are used to assess the effects of treatment (mean procedure time), the mean difference (MD) is used, or the standardised mean difference (SMD) if different scales were used.
Unit of analysis issues
The first period of cross-over studies was to be included.
Assessment of heterogeneity
Heterogeneity was analysed using a Chi² test on N-1 degrees of freedom, with an alpha of 0.05 used for statistical significance and with the I² test (Higgins 2003) . I² values of 25%, 50% and 75% correspond to low, medium and high levels of heterogeneity.
R E S U L T S Description of studies
See: Characteristics of included studies and Characteristics of excluded studies.
Results of the search
Forty reports were retrieved as identified in the Cochrane Kidney and Transplant Specialised Register and further four reports were retrieved via a cross-link search. These 44 reports were screened (titles, abstracts and full-text) and seven studies (eight reports) fulfilled our inclusion criteria (see Figure 1) .
Figure 1. Flow diagram showing article selection process
Prior to publication of this review a final search of the Specialised Register identified one new potential study (Krishna Reddy 2014) and one ongoing study (NCT01754779) and these will be assessed for inclusion in a future update of this review. 
Sample sizes
These seven studies reported the results for 477 participants. One hundred and sixty one participants had residual stones < 5 mm post ESWL/PCNL; the remaining 316 participants were stonefree at the start of the study but were active stone formers.
Setting
Five studies were conducted at a university teaching hospital (Ettinger 1997; Hofbauer 1994; Jimenez Verdejo 2001; Lojanapiwat 2011; Soygur 2002); one study was conducted at a general hospital with university links (Cicerello 1994) and one study was conducted at a private hospital with university links (Barcelo 1993).
Participants
Selection criteria varied among included studies.
• Ettinger 1997 included patients with two or more calculi within the previous five years and at least one calculus within the year prior to recruitment.
• Barcelo 1993 selected patients with moderately severe active urolithiasis (two or more stones formed during the previous two years composed of calcium oxalate or a mixture of calcium oxalate and calcium phosphate) with low or low normal urinary citrate.
• Hofbauer 1994 recruited patients with recurrent idiopathic calcium oxalate urolithiasis (at least one stone over the previous three years).
• Lojanapiwat 2011 studied patients who were stone-free or had residual stones < 4 mm following ESWL or PCNL.
• Soygur 2002 and Jimenez Verdejo 2001 enrolled post shock wave lithotripsy (SWL) patients who were either stone-free or residual stones of < 5 mm or < 2 mm respectively.
• Cicerello 1994 recruited patients with residual fragments < 5 mm post ESWL as well as patients with struvite stones, the struvite stone patients were excluded from analysis in this review. The remaining 24 studies were RCTs that investigated interventions for kidney stones that did not meet our inclusion criteria.
Interventions
• Three studies (Gao 2010; Sarica 2006a; Schell-Feith 2006) had patient population age of less than 16 years of age.
• Fourteen studies ( • In four studies (Ettinger 1976; Fernandez Rodriguez 2001; LIMONE Study 2012; Mortensen 1986) a different intervention was used. i.e. potassium acid phosphate, thiazide, citric acid.
• Two studies (Premgamone 2001; Singh 2012) citrate was used in the control group (i.e. no control arm).
• One study (Pak 1992) assessed only biochemical parameters.
Risk of bias in included studies
In general the risk of bias of the included studies as judged by the authors was low ( 
Blinding
Two studies were reported as double-blind RCTs (Barcelo 1993; Ettinger 1997). Ettinger 1997 described blinding of an outcome assessor who reviewed the X-ray films, and Cicerello 1994 reported the radiologist who reviewed the interval imaging was unaware of the study protocol.
Incomplete outcome data
In five studies the number of participants randomised matched the number reported in the results ().
• Barcelo 1993 excluded dropouts from the main analysis but did report outcomes of five non-compliant participants with continued follow-up. No interim results were reported for 11 participants who dropped out due to non-compliance.
• Soygur 2002 did not report results in 20/110 participants who were enrolled in the study, they described randomisation of 90 participants and these are included in the results. They later report 20 dropouts, of whom six dropped out due to epigastric discomfort. We have therefore presumed that all 110 were enrolled and randomised but results for the 90 completing the study are reported.
• Lojanapiwat 2011 enrolled 80 participants; results were reported for 76, no explanation was provided about which group the dropouts belonged to.
Other potential sources of bias
Barcelo 1993 reported a difference in the dosing regimen from the study protocol dosing regimen. The participants allocated to the treatment arm were to take 60 mEq/day of potassium citrate however average consumption was 45 mEq/day and participants taking less than 30 mEq/day were excluded. Unfortunately the final results do not specify which dosing regimen was most effective in stone prevention. 
Effects of interventions Reduction in stone size
D I S C U S S I O N
Summary of main results
Citrate salts are an effective intervention in the treatment and prevention of kidney stones. The evidence from seven RCTs included in this review has demonstrated good efficacy with citrate therapy compared to control (placebo, usual care). However, this review was unable to demonstrate the most effective type and dose of citrate salt needed to achieve this clinical benefit. The precise duration of treatment remains to be defined. Interestingly, dropout rate due to side effects is low.
Overall completeness and applicability of evidence
We conducted a comprehensive search of the databases and included the non-English language literature. Two review authors independently assessed the material to minimise errors, and a third author was consulted to resolve any disputes. During the initial part of review process, we excluded the RCT by Cicerello 1994 as it did not meet our inclusion criteria of patients aged 18 year or more. However, it was felt that this is an important study and accordingly our initial inclusion criteria was altered to include patients over 16 years of age. We attempted to contact two authors for further clarification of data without success. The included studies were assessed for reporting completeness by using the CON-SORT 2010 checklist (Schulz 2010) however, we took into consideration that six studies were published prior to these guidelines (Barcelo 1993
or post-PCNL) with residual stones and were able to demonstrate a significant benefit of citrate therapy in stone size reduction and stone size stability. Overall, evidence for specific citrate treatment is limited due to use of different citrate salts at varying dosage, varying follow-up periods, and varying follow-up imaging protocols. Despite significant benefit of citrate salts in prevention and treatment of kidney stones these limitations, make it difficult to recommend a specific salt in day-to-day practice.
Quality of the evidence
The seven RCTs included in this review have used different citrate salts at varying doses. Length of follow-up also varied between the studies. Power calculations have not been reported by any of the studies. Barcelo 1993 and Ettinger 1997 are double-blind and have a good description of blinding; however the overall description of study methodology by Barcelo 1993 was poor as assessed by the CONSORT 2010 checklist (Schulz 2010). The level of heterogeneity reported for outcomes assessing treatment of stone disease was low, but this was not the case when analysis was carried out on new stone formation where the level was high: I² = 80%, and was attributed to Hofbauer 1994. A moderate-strength evidence (RR, 0.25, 95% CI 0.14 to 0.44) was observed in a recent review (Fink 2012). Studies with over 12 months follow-up took serial X-rays at sixmonthly intervals (Barcelo 1993; Ettinger 1997; Hofbauer 1994; Jimenez Verdejo 2001). Interestingly, the individual data for stone growth or new stone formation at various intervals has not been reported in any of the studies. It is therefore impossible to comment on the exact time where change in the stone size did occur and hence optimal duration of therapy cannot be defined. In three studies (Cicerello 1994; Lojanapiwat 2011; Soygur 2002) with up to 12 months follow-up, new stone formation varied from 0% to 8% in the treatment arm and 29% to 42% in the control arm. Among studies that reported > 12 months follow-up (Barcelo 1993; Ettinger 1997; Hofbauer 1994; Jimenez Verdejo 2001), the percentage of patients with new stones varied from 8% to 69% in the treatment arm and 44% to 73% in the control arm. Interestingly, Hofbauer 1994 was the only study that failed to demon-strate any difference in new stone formation between treatment and control arms. this study utilised a method of altering the dose of citrate to maintain urine pH at 7.2. This was considerably more alkaline than reported by the other studies which reported pH of 6.29 to 6.64. Eleven of 16 participants in the treatment arm reported new stone formation; only one of these was reported as a calcium phosphate stone. Authors failed to report on the number of stones analysed in the laboratory, therefore, it could be postulated that the high pH may have attributed to more calcium phosphate stone formation although the crystal inhibitory effect of citrate due to the presence of high citrate levels in the urine should counterbalance the pH effect on calcium phosphate saturation. Another explanation could be the higher intake of sodium increased calcium excretion and therefore promoted new stone formation.
Potential biases in the review process
The quality of the included RCTs was moderate to poor which can reduce the reliability of the estimates of the effectiveness of citrate salts. We attempted to improve reliability by contacting two authors for missing data however we were unsuccessful in obtaining any further details.
Agreements and disagreements with other studies or reviews
Fink 2012 produced a comprehensive systematic review on the medical management to prevent recurrent nephrolithiasis this included the use of citrate salts. Their findings compliment ours. Pearle 1999 described the use of citrate salts in a meta-analysis on treatment options for calcium oxalate stones. There was insufficient evidence at the time to analyse the effects of this treatment and reported insufficient evidence.
A U T H O R S ' C O N C L U S I O N S
Implications for practice
Citrate salts are currently in use for the treatment and prevention of calcium-containing kidney stones, this review has highlighted the evidence that there is some beneficial effect of prescribing this medicine particularly to prevent new stone formation. The administration of citrate salts has been shown to increase excretion of citrate in the urine. Which citrate salt is most favourable remains an unanswered question. While there were more adverse events reported with citrate therapy, this was not significant. These findings must be considered in the context of moderate to poor study design and incomplete outcome reporting. Consideration also needs to be made to the economic value of prescribing citrate salts in the long-term; this is one area which has not been addressed.
Implications for research
This review highlights the lack of good quality reported literature in the use of citrate salts for kidney stone management. A multicentre study which compares different citrate salts in patients who are stone-free, recurrent stone formers or have residual fragments < 4 mm to placebo is required. The primary outcomes should be new stone formation, stone growth, visits to the emergency department, proven renal colic or intervention for stones. Alterations in the urinary parameters should be included as secondary outcomes. A complete metabolic work up according to European guidelines at baseline, and six monthly thereafter should be considered. Gold standard CT KUB should be used for assessment allowing all types of stones to be studied. The study should incorporate interval reporting at 6, 12 and 24 months so evidence can be gathered on the long term benefits of using citrate salts. Adverse events should be reported thoroughly and specify if patients dropped out due to an event. Future studies should report on the health economics of citrate salts in preventing new stone formation after interventions (ESWL, PCNL and ureteroscopy) and their impact on the growth of residual fragments. 
LIMONE Study 2012 {published data only}
C H A R A C T E R I S T I C S O F S T U D I E S Characteristics of included studies [ordered by study ID]
Barcelo 1993
Methods
Outcomes
Outcome measures • X-ray, blood and urine analyses were taken at baseline and 6 monthly intervals Outcome definitions
• Stone growth represented an increase of more than 100% in stone size as seen on the X-ray
• New stone formation represented spontaneous passage in the absence of preexisting stones, stone passage without any change in the number of stones, appearance of new stones on the X-ray or newly formed stones requiring ESWL or surgical removal
Notes
• Average tablet consumption was 9/d, non-compliance set at tablet consumption of ≤ 6 tablets/d
• End of treatment citrate not reported for control group • Dropouts excluded from study analysis • Advised fluid intake to achieve a daily urine output of more than 2.5 L and to avoid dietary excess
• The infective stone formers were given full dose antibiotics for 10 d/mo Control group
• Advised fluid intake to achieve a daily urine output of more than 2.5 L and to avoid dietary excess
Cicerello 1994 (Continued)
• The infective stone formers were given full dose antibiotics for 10 d/mo 
A D D I T I O N A L T A B L E S
